Questions Persist On Lilly’s Tirzepatide And Tolerability
Executive Summary
Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly believes the adverse events are manageable.
You may also be interested in...
Lilly’s Tirzepatide Effective, But Tolerability Still A Limitation
Tirzepatide’s efficacy seems to outweigh tolerability concerns at the lower doses, but the highest dose may be relegated to niche use.
Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market
Starting patients on a low dose yielded lower rates of GI adverse events for the GIP/GLP-1 agonist, but it remains uncertain how differentiated tirzepatide will be against entrenched GLP-1 rivals.
Lilly, Galapagos Put Some Trials On Hold Due To Coronavirus Concerns
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.